{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T01:08:02Z","timestamp":1706317682038},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Il Farmaco"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1016\/j.farmac.2005.05.009","type":"journal-article","created":{"date-parts":[[2005,6,17]],"date-time":"2005-06-17T23:13:11Z","timestamp":1119049991000},"page":"653-663","source":"Crossref","is-referenced-by-count":3,"title":["2,1,3-Benzothiadiazine derivatives: synthesis and screening versus PDE4 enzyme"],"prefix":"10.1016","volume":"60","author":[{"given":"Annalisa","family":"Tait","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"Luppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Baraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.farmac.2005.05.009_bib1","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0006-2952(98)00331-1","article-title":"Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation","volume":"57","author":"Essayan","year":"1999","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.farmac.2005.05.009_bib2","doi-asserted-by":"crossref","first-page":"5493","DOI":"10.1074\/jbc.R200029200","article-title":"Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signalling","volume":"278","author":"Conti","year":"2003","journal-title":"Biol. Chem."},{"key":"10.1016\/j.farmac.2005.05.009_bib3","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.4049\/jimmunol.147.5.1628","article-title":"RaplA is a substrate for cyclic AMP-dependent protein kinase in human neutrophils","volume":"147","author":"Quilliam","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.farmac.2005.05.009_bib4","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1002\/j.1460-2075.1994.tb06797.x","article-title":"Goals for signal transduction pathways: linking up transcriptional regulation","volume":"13","author":"Sassone-Corsi","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.farmac.2005.05.009_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jlb.52.4.400","article-title":"Reversal of inhibitory pathways in neutrophils by protein kinase antagonist: a rational approach to the restoration of depressed cell function?","volume":"52","author":"Mueller","year":"1992","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.farmac.2005.05.009_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0006-2952(90)90304-4","article-title":"Differential inhibition of human neutrophils function. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase","volume":"40","author":"Wright","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.farmac.2005.05.009_bib7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0922-4106(94)90067-1","article-title":"Nimesulide decrease super-oxide production by inhibiting phosphodiesterase type IV","volume":"268","author":"Bevilacqua","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.farmac.2005.05.009_bib8","series-title":"Phosphodiesterase Inhibitors","author":"Dent","year":"1997"},{"issue":"Suppl. 2","key":"10.1016\/j.farmac.2005.05.009_bib9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2222.1999.00018.x","article-title":"Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease","volume":"29","author":"Schmidt","year":"1999","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.farmac.2005.05.009_bib10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0165-6147(97)01049-3","article-title":"Phosphodiesterase (PDE4) inhibitors: anti-inflammatory drugs of the future?","volume":"18","author":"Teixeira","year":"1997","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.farmac.2005.05.009_bib11","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/1381612023394665","article-title":"Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs","volume":"8","author":"Burnouf","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.farmac.2005.05.009_bib12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/s-2007-1017435","article-title":"Results of a phase II study of the antidepressant effect of rolipram","volume":"17","author":"Zeller","year":"1984","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.farmac.2005.05.009_bib13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0028-3908(00)00142-8","article-title":"PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway","volume":"40","author":"Robichaud","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.farmac.2005.05.009_bib14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-2007-1014599","article-title":"(+)-Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine","volume":"22","author":"Hebenstreit","year":"1989","journal-title":"Pharmacopsychiatry"},{"issue":"23","key":"10.1016\/j.farmac.2005.05.009_bib15","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.2165\/00003495-200363230-00002","article-title":"Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease","volume":"63","author":"Spina","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.farmac.2005.05.009_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0140-6736(01)05481-2","article-title":"Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study","volume":"358","author":"Compton","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.farmac.2005.05.009_bib17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1067\/mai.2001.118596","article-title":"The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis","volume":"108","author":"Schmidt","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.farmac.2005.05.009_bib18","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1183\/09031936.93.05080982","article-title":"Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma","volume":"5","author":"Brunnee","year":"1992","journal-title":"Eur. J. Respir."},{"key":"10.1016\/j.farmac.2005.05.009_bib19","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1021\/jm010837k","article-title":"Novel selective PDE4 inhibitors. 1. Synthesis, structure\u2013activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues","volume":"44","author":"Van der Mey","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.farmac.2005.05.009_bib20","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/S0960-894X(00)00548-5","article-title":"Synthesis and biological evaluation of 2,5-dihydropyrazolo[4,3-c]quinolin-3-ones, a novel series of PDE 4 inhibitors with low emetic potential and antiasthmatic properties","volume":"10","author":"Crespo","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.farmac.2005.05.009_bib21","series-title":"6,5-Fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity, US-6075016","author":"Chasin","year":"2000"},{"key":"10.1016\/j.farmac.2005.05.009_bib22","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1021\/jm990382n","article-title":"Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors","volume":"43","author":"Martinez","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.farmac.2005.05.009_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0223-5234(01)01227-2","article-title":"CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors","volume":"36","author":"Castro","year":"2001","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.farmac.2005.05.009_bib24","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.bmc.2004.10.055","article-title":"Synthesis, biological evaluation and molecular modeling studies on benzothiadiazine derivatives as PDE4 selective inhibitors","volume":"13","author":"Tait","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.farmac.2005.05.009_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.bjp.0705770","article-title":"Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells","volume":"142","author":"Shepherd","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.farmac.2005.05.009_bib26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/jhet.5570410516","article-title":"Synthesis and antiviral activity of new benzothiadiazine dioxide derivatives","volume":"41","author":"Tait","year":"2004","journal-title":"J. Het. Chem."},{"key":"10.1016\/j.farmac.2005.05.009_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-1981-29317","article-title":"The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products","author":"Mitsunobu","year":"1981","journal-title":"Synthesis"},{"key":"10.1016\/j.farmac.2005.05.009_bib28","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1021\/ja00869a044","article-title":"Sulfamoyl chloride, sulfamides and sulfimide","volume":"84","author":"Cohen","year":"1962","journal-title":"J. Am. Chem. Soc."},{"issue":"41","key":"10.1016\/j.farmac.2005.05.009_bib29","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1021\/jo00887a022","article-title":"An improved synthesis of sulfamoyl chlorides","volume":"25","author":"Kloek","year":"1976","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.farmac.2005.05.009_bib30","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1021\/jo00168a058","article-title":"Esterification using a polymer-supported phosphine reagent","volume":"48","author":"Amos","year":"1983","journal-title":"J. Org. Chem."},{"issue":"35","key":"10.1016\/j.farmac.2005.05.009_bib31","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1016\/0040-4039(95)01247-F","article-title":"Polymer-supported Mitsunobu ether formation and its use in combinatorial chemistry","volume":"36","author":"Krchn\u00e0k","year":"1995","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.farmac.2005.05.009_bib32","doi-asserted-by":"crossref","first-page":"8751","DOI":"10.1016\/S0040-4039(98)01988-1","article-title":"Polymer-bound triphenylphosphine as traceless reagent for Mitsunobu reactions in combinatorial chemistry: synthesis of aryl ethers from phenols and alcohols","volume":"39","author":"Tunoori","year":"1998","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.farmac.2005.05.009_bib33","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/S0040-4039(02)00222-8","article-title":"Synthesis of aryl ethers from aminoalcohols using polymer-supported triphenylphosphine","volume":"43","author":"Lizarzaburu","year":"2002","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.farmac.2005.05.009_bib34","doi-asserted-by":"crossref","first-page":"12405","DOI":"10.1016\/S0040-4020(99)00723-1","article-title":"On the tautomerism of 2,1,3-benzothiadiazine S,S-dioxide and related compounds","volume":"55","author":"Castro","year":"1999","journal-title":"Tetrahedron"},{"key":"10.1016\/j.farmac.2005.05.009_bib35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/cber.19650980122","article-title":"Reduktion terti\u00e4rer phosphinoxyde zu terti\u00e4ren phosphinen mit trichlorosilan","volume":"98","author":"Fritsche","year":"1965","journal-title":"Chem. Ber."},{"issue":"11","key":"10.1016\/j.farmac.2005.05.009_bib36","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1021\/jo00899a042","article-title":"Solid phase phosphorus reagents. Conversion of alcohols to alkyl chlorides","volume":"40","author":"Regen","year":"1975","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.farmac.2005.05.009_bib37","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1021\/jm000118q","article-title":"Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives","volume":"43","author":"Mart\u00ecnez","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.farmac.2005.05.009_bib38","series-title":"Herbicidal benzothiadiazinone, DE-2165555","author":"Fischer","year":"1973"},{"key":"10.1016\/j.farmac.2005.05.009_bib39","series-title":"Process for the economical production of 3-isopropyl-2,1,3-benzothiadiazine-4-one 2,2-dioxide, HU-56837","author":"Damjan","year":"1991"},{"key":"10.1016\/j.farmac.2005.05.009_bib40","series-title":"Postemergent herbicidal method using 8-substituted benzothiadiaziones, US-4155746","author":"McKendry","year":"1979"},{"key":"10.1016\/j.farmac.2005.05.009_bib41","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0040-4020(95)00932-9","article-title":"Synthesis of pseudonucleosides containing chiral sulfahydantoins as aglycone (II)","volume":"52","author":"Dewynter","year":"1996","journal-title":"Tetrahedron"},{"key":"10.1016\/j.farmac.2005.05.009_bib42","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1021\/jm000033p","article-title":"Benzothiadiazine dioxide dibenzyl derivatives as potent human cytomegalovirus inhibitors: synthesis and comparative molecular field analysis","volume":"43","author":"Martinez","year":"2000","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.farmac.2005.05.009_bib43","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/095632020101200604","article-title":"Anti-HIV-1 activity of benzothiadiazine dioxide","volume":"12","author":"Martinez","year":"2002","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.farmac.2005.05.009_bib44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0898-6568(95)02010-1","article-title":"Phospholipid regulation of a cyclic AMP-specific phosphodiesterase (PDE4) from U937 cells","volume":"7","author":"Di Santo","year":"1995","journal-title":"Cell. Signal."},{"key":"10.1016\/j.farmac.2005.05.009_bib45","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1042\/0264-6021:3470571","article-title":"Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells","volume":"347","author":"MacKenzie","year":"2000","journal-title":"Biochem. J."},{"key":"10.1016\/j.farmac.2005.05.009_bib46","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0091-6749(05)80186-1","article-title":"Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst","volume":"86","author":"Nielson","year":"1990","journal-title":"J. All. Clin. Immunol."}],"container-title":["Il Farmaco"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014827X05001163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014827X05001163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T23:59:46Z","timestamp":1706313586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014827X05001163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0014827X05001163"],"URL":"https:\/\/doi.org\/10.1016\/j.farmac.2005.05.009","relation":{},"ISSN":["0014-827X"],"issn-type":[{"value":"0014-827X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}